Targacept reverse merges with Catalyst Biosciences
Publicly traded Targacept Inc. reverse merged with fellow biotech, privately held Catalyst Biosciences Inc. The combined entity will retain Catalyst's name, will be owned 65% by Catalyst's investors (subject to adjustment), and is expected to have $40mm in cash at closing ($35mm from Targacept and the rest from Catalyst). The new board will have four Catalyst and three Targacept directors.
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.